192 related articles for article (PubMed ID: 20141428)
1. The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant.
Alousi AM; Uberti J; Ratanatharathorn V
Leuk Lymphoma; 2010 Mar; 51(3):376-89. PubMed ID: 20141428
[TBL] [Abstract][Full Text] [Related]
2. B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy.
Kim SJ; Won JH
Leuk Lymphoma; 2012 Jan; 53(1):19-25. PubMed ID: 21740304
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.
Kharfan-Dabaja MA; Bazarbachi A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1347-54. PubMed ID: 20083213
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects.
Ratanatharathorn V; Pavletic S; Uberti JP
Cancer Treat Rev; 2009 Dec; 35(8):653-61. PubMed ID: 19682801
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for prevention and treatment of graft-versus-host disease.
Kharfan-Dabaja MA; Cutler CS
Int J Hematol; 2011 May; 93(5):578-585. PubMed ID: 21547615
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.
Arai S; Sahaf B; Narasimhan B; Chen GL; Jones CD; Lowsky R; Shizuru JA; Johnston LJ; Laport GG; Weng WK; Benjamin JE; Schaenman J; Brown J; Ramirez J; Zehnder JL; Negrin RS; Miklos DB
Blood; 2012 Jun; 119(25):6145-54. PubMed ID: 22563089
[TBL] [Abstract][Full Text] [Related]
8. B cells in chronic graft-versus-host disease.
Sarantopoulos S; Blazar BR; Cutler C; Ritz J
Biol Blood Marrow Transplant; 2015 Jan; 21(1):16-23. PubMed ID: 25452031
[TBL] [Abstract][Full Text] [Related]
9. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes Compared with Fludarabine and Busulfan after Allogeneic Stem Cell Transplantation for B Cell Malignancies.
Kennedy VE; Savani BN; Greer JP; Kassim AA; Engelhardt BG; Goodman SA; Sengsayadeth S; Chinratanalab W; Jagasia M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1801-1807. PubMed ID: 27377900
[TBL] [Abstract][Full Text] [Related]
10. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.
Crocchiolo R; Castagna L; El-Cheikh J; Helvig A; Fürst S; Faucher C; Vazquez A; Granata A; Coso D; Bouabdallah R; Blaise D
Exp Hematol; 2011 Sep; 39(9):892-6. PubMed ID: 21703987
[TBL] [Abstract][Full Text] [Related]
11. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
Simpson D
BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of rituximab in chronic graft-versus-host disease.
Bates JS; Engemann AM; Hammond JM
Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
[TBL] [Abstract][Full Text] [Related]
13. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Bryant A; Mallick R; Huebsch L; Allan D; Atkins H; Anstee G; Sabloff M; Scrivens N; Maze D; Bredeson C; Kekre N
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2096-2101. PubMed ID: 28821454
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab.
Kennedy VE; Sahaf B; Wu F; Ehlinger ZJ; Arai S; Miklos DB
Transplant Cell Ther; 2024 May; 30(5):518.e1-518.e13. PubMed ID: 38458479
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD.
van Dorp S; Pietersma F; Wölfl M; Verdonck LF; Petersen EJ; Lokhorst HM; Martens E; Theobald M; van Baarle D; Meijer E; Kuball J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):671-8. PubMed ID: 19450751
[TBL] [Abstract][Full Text] [Related]
16. Towards a rational graft-versus-host disease (GVHD) prophylaxis: rituximab should not be forgotten.
Van Hoef ME
Haematologica; 2013 Apr; 98(4):e40-1. PubMed ID: 23543154
[No Abstract] [Full Text] [Related]
17. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
19. [Use of monoclonal antibodies in prophylaxis and treatment of acute and chronic graft-versus-host disease in 2011].
Xhaard A; Hermet E; Bay JO; Peffault de Latour R
Bull Cancer; 2011 Aug; 98(8):889-99. PubMed ID: 21835730
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in hematopoietic cell transplantation.
Arai S; Miklos DB
Expert Opin Biol Ther; 2010 Jun; 10(6):971-82. PubMed ID: 20420511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
